Yongin, South Korea · Founded 2018 · Privately Held (backing)
Developer of PEGylated bilirubin nanoparticles designed to treat ischemia-reperfusion injury by reducing inflammation and oxidative stress. Bilix is based in Yongin, South Korea and was founded in 2018. Its last reported valuation was $28.1 million in Dec 2025. It has raised $10 million.
Last reported valuation
$28.1M
Oct 2026
Priced at
—
Total raised
$10.0M
Last round
—
Cap table — not yet on record
Bilix's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Bilix with a free account
·The complete investor list: 15 names
·Watch Bilix: the Monday email on marks, rounds and moves
